Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed ...

A highly expensive, revolutionary treatment for recurrent prostate cancer is for the first time in Australia available at a ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

(UroToday.com) The Interdisciplinary Genitourinary Cancer Forum 2025, held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 2: Local Treatments. Dr. Peter Carroll ...

Mogensen AW et al. The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer ...

June 17, 2025 0 60 By Edward M. Soffen, MD After skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the United States.

International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane ...

Updated American Urologic Association (AUA) guidelines presented at the 2025 annual meeting mark a major shift in the management of prostate cancer recurrence, moving away from routine adjuvant ...

Cite this: ASCO 2025: Highlights in Prostate Cancer Biomarkers and Therapies - Medscape - June 06, 2025.